Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-market Registry of the BioMatrix Alpha TM (Cobalt Chromium Biolimus A9TM (BA9TM) Drug-eluting Stent)

NCT02871622 is registered in ClinicalTrials.gov with Biosensors Europe SA as lead sponsor.

NCT NCT02871622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02871622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-market Registry of the BioMatrix Alpha TM (Cobalt Chromium Biolimus A9TM (BA9TM) Drug-eluting Stent)
Lead sponsor
Biosensors Europe SA
Phase
Observational
Overall status
Unknown status
Start date
September 30, 2016
Completion date
October 31, 2019
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, coronary artery disease, ischemia, nstemi, stable angina, stemi